Clinical research treating mental illness with psychedelics has been ongoing for decades, but now there's a group of companies exclusively focused on using LSD and other psychedelics to treat mental health disorders.
Dan digs into the argument for legalizing prescription psychedelics, and the treacherous FDA approval path, with MindMed CEO JR Rahn, whose company recently listed on the Nasdaq.
The push to legalize psychedelics for mental health | Axios Re:Cap podcast - Listen or read transcript on Metacast
